Ranolazine is an anti-arrhythmic drug that targets voltage-gated sodium channels. Lenaeus et al. present a cryo-EM structure of the cardiac sodium channel bound to ranolazine to demonstrate that this compound acts as a structural clamp that inhibits the channels.
This is a preview of subscription content, log in via an institution to check access.
References
Abriel, H. J. Mol. Cell Cardiol. 48, 2–11 (2010).
Clancy, C. E. et al. J. Physiol. 593, 1331–1345 (2015).
Roden, D. M. Card. Electrophysiol. Clin. 6, 695–704 (2014).
Ragsdale, D. S. et al. Science 265, 1724–1728 (1994).
Horvath, B. et al. Front. Pharmacol. 11, 413 (2020).
Li, Z. et al. Angew. Chem. Int. Ed. Engl. 60, 11474–11480 (2021).
Jiang, D. et al. Cell 180, 122–134 (2019).
Lenaeus, M. et al. Nat. Cardiovasc. Res. https://doi.org/10.1038/s44161-023-00271-5 (2023).
Fuller, H. et al. Heart Rhythm 13, 1679–1686 (2016).
Chakouri, N. et al. Nat. Cardiovasc. Res. 1, 1–13 (2022).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no competing interests.
Rights and permissions
About this article
Cite this article
Fossier, L., Ben-Johny, M. New insights on cardiac Na channel block by an atypical anti-arrhythmic drug. Nat Cardiovasc Res 2, 494–495 (2023). https://doi.org/10.1038/s44161-023-00284-0
Published:
Issue Date:
DOI: https://doi.org/10.1038/s44161-023-00284-0
- Springer Nature Limited